Nuvectis Pharma (NVCT) Net Income towards Common Stockholders (2021 - 2026)

Nuvectis Pharma has disclosed Net Income towards Common Stockholders across 6 years of filings, most recently posting -$6.0 million for Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at -$6.0 million, down 13.47% year-over-year; the trailing twelve-month figure through Mar 2026 was -$29.6 million (down 46.76% YoY), and the FY2025 annual result was -$28.9 million, down 51.95% from the prior year.
• Net Income towards Common Stockholders came in at -$6.0 million for Q1 2026 at Nuvectis Pharma, up from -$7.3 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$2.9 million in Q1 2022 to a low of -$9.9 million in Q3 2025.
• The 5-year median for Net Income towards Common Stockholders is -$5.9 million (2022), against an average of -$5.6 million.
• Peak annual rise in Net Income towards Common Stockholders reached 39.9% in 2022, while the deepest fall reached 12695.65% in 2022.
• Nuvectis Pharma's Net Income towards Common Stockholders stood at -$6.7 million in 2022, then gained by 1.11% to -$6.6 million in 2023, then grew by 5.65% to -$6.2 million in 2024, then decreased by 17.06% to -$7.3 million in 2025, then increased by 17.28% to -$6.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$6.0 million (Q1 2026), -$7.3 million (Q4 2025), and -$9.9 million (Q3 2025), per Business Quant data.